skip to Main Content

Dr. Katz on Neoadjuvant Chemotherapy in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Matthew H.G. Katz, MD, FACS, associate professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the benefit of neoadjuvant chemotherapy in patients with pancreatic cancer.

One of the underlying rationales for giving preoperative therapy to patients with pancreatic cancer is to select those with rapidly progressive disease, particularly those who are not anticipated to benefit from an operation, prior to undergoing what would otherwise be a complex and potentially morbid operation, says Katz. Watch here. . . 

Back To Top